Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol added to RAAS blockade and sodium diet modification for albuminuria in chronic kidney disease
NL-OMON40020Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paricalcitol in chronic kidney disease (CKD) (4 arms), sponsored by University Medical Center Groningen. Primary endpoint: 24-hour urinary albumin excretion. Started Dec 2012; status: active, not recruiting.
02
Drugs
paricalcitol
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON40020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40020.